Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G F Fleming

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|January 15, 1997
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2aG F Fleming, S E Waggoner, S Wu, et al.
Pharmacy World & Science : PWS|May 10, 2001
The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/WalesG F Fleming, J C McElnay, C M Hughes, et al.
Gynecologic Oncology|April 1, 1997
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancerG F Fleming, S E Waggoner, J Rotmensch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2003
Invariant p53 immunostaining in primary and recurrent breast cancerS M Poelman, R Heimann, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyG F Fleming, O Pagani, M M Regan, et al.
Cancer|June 1, 1996
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor supportG F Fleming, L Janisch, N J Vogelzang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesisG F Fleming, E E Vokes, J M McEvilly, et al.
Gynecologic Oncology|September 5, 2001
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignanciesA J Mundt, J Rotmensch, S E Waggoner, et al.
Bone Marrow Transplantation|May 22, 2001
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancerG G Laport, G F Fleming, S Waggoner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group studyG F Fleming, V L Filiaci, R C Bentley, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|January 15, 1997
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2aG F Fleming, S E Waggoner, S Wu, et al.
Pharmacy World & Science : PWS|May 10, 2001
The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/WalesG F Fleming, J C McElnay, C M Hughes, et al.
Gynecologic Oncology|April 1, 1997
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancerG F Fleming, S E Waggoner, J Rotmensch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2003
Invariant p53 immunostaining in primary and recurrent breast cancerS M Poelman, R Heimann, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyG F Fleming, O Pagani, M M Regan, et al.
Cancer|June 1, 1996
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor supportG F Fleming, L Janisch, N J Vogelzang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesisG F Fleming, E E Vokes, J M McEvilly, et al.
Gynecologic Oncology|September 5, 2001
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignanciesA J Mundt, J Rotmensch, S E Waggoner, et al.
Bone Marrow Transplantation|May 22, 2001
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancerG G Laport, G F Fleming, S Waggoner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group studyG F Fleming, V L Filiaci, R C Bentley, et al.
Pageof 6